APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Attenuated Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Attenuated Vaccine Industry Growth and Trends Forecast to 2032

Report ID 173968240129 December 2025109 pages

Choose your research edition.

Industry ResearchAttenuated Vaccine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Attenuated Vaccine Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Attenuated Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Attenuated Vaccine Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Attenuated Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Attenuated Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Attenuated Vaccine include Changchun BCHT Biotechnology Co.,Ltd, Shanghai Rongsheng Biotech, Sanofi, Johnson & Johnson, Merck & Co., Pfizer Inc, GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd. and Green Cross Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Attenuated Vaccine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Attenuated Vaccine market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Attenuated Vaccine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Attenuated Vaccine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Attenuated Vaccine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Attenuated Vaccine Market by Company

Changchun BCHT Biotechnology Co.,Ltd

Shanghai Rongsheng Biotech

Sanofi

Johnson & Johnson

Merck & Co.

Pfizer Inc

GlaxoSmithKline plc

Serum Institute of India Pvt. Ltd.

Green Cross Corporation

CSL Limited

Biken

Astellas Pharma

Attenuated Vaccine Segment by Type

Bacterial Vaccine

Viral Vaccine

Attenuated Vaccine Segment by Application

Hospital

Clinic

Others

Attenuated Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attenuated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Attenuated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attenuated Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Attenuated Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Attenuated Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Bacterial Vaccine Table 2. Major Company of Viral Vaccine Table 3. Global Attenuated Vaccine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Attenuated Vaccine Sales by Type (2021-2026) & (K Units) Table 5. Global Attenuated Vaccine Sales Market Share in Volume by Type (2021-2026) Table 6. Global Attenuated Vaccine Sales by Type (2021-2026) & (US$ Million) Table 7. Global Attenuated Vaccine Sales Market Share in Value by Type (2021-2026) Table 8. Global Attenuated Vaccine Price by Type (2021-2026) & (US$/Unit) Table 9. Global Attenuated Vaccine Sales by Type (2027-2032) & (K Units) Table 10. Global Attenuated Vaccine Sales Market Share in Volume by Type (2027-2032) Table 11. Global Attenuated Vaccine Sales by Type (2027-2032) & (US$ Million) Table 12. Global Attenuated Vaccine Sales Market Share in Value by Type (2027-2032) Table 13. Global Attenuated Vaccine Price by Type (2027-2032) & (US$/Unit) Table 14. North America Attenuated Vaccine Sales by Type (2021-2026) & (K Units) Table 15. North America Attenuated Vaccine Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Attenuated Vaccine Sales by Type (2021-2026) & (K Units) Table 17. Europe Attenuated Vaccine Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Attenuated Vaccine Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Attenuated Vaccine Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Attenuated Vaccine Sales by Type (2021-2026) & (K Units) Table 21. Latin America Attenuated Vaccine Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Attenuated Vaccine Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Attenuated Vaccine Sales by Type (2021-2026) & (US$ Million) Table 24. Attenuated Vaccine Industry Trends Table 25. Attenuated Vaccine Industry Drivers Table 26. Attenuated Vaccine Industry Opportunities and Challenges Table 27. Attenuated Vaccine Industry Restraints Table 28. Global Attenuated Vaccine Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Attenuated Vaccine Revenue Market Share by Company (2021-2026) Table 30. Global Attenuated Vaccine Sales by Company (2021-2026) & (K Units) Table 31. Global Attenuated Vaccine Sales Share by Company (2021-2026) Table 32. Global Attenuated Vaccine Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Attenuated Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Attenuated Vaccine Major Company Production Sites and Headquarters Table 35. Global Attenuated Vaccine Company, Product Type & Application Table 36. Global Attenuated Vaccine Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Attenuated Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Attenuated Vaccine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Attenuated Vaccine Sales by Region (2021-2026) & (K Units) Table 41. Global Attenuated Vaccine Sales Market Share in Volume by Region (2021-2026) Table 42. Global Attenuated Vaccine Sales by Region (2021-2026) & (US$ Million) Table 43. Global Attenuated Vaccine Sales Market Share in Value by Region (2021-2026) Table 44. Global Attenuated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Attenuated Vaccine Sales by Region (2027-2032) & (K Units) Table 46. Global Attenuated Vaccine Sales Market Share in Volume by Region (2027-2032) Table 47. Global Attenuated Vaccine Sales by Region (2027-2032) & (US$ Million) Table 48. Global Attenuated Vaccine Sales Market Share in Value by Region (2027-2032) Table 49. Global Attenuated Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Attenuated Vaccine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Attenuated Vaccine Sales by Application (2021-2026) & (K Units) Table 52. Global Attenuated Vaccine Sales Market Share in Volume by Application (2021-2026) Table 53. Global Attenuated Vaccine Sales by Application (2021-2026) & (US$ Million) Table 54. Global Attenuated Vaccine Sales Market Share in Value by Application (2021-2026) Table 55. Global Attenuated Vaccine Price by Application (2021-2026) & (US$/Unit) Table 56. Global Attenuated Vaccine Sales by Application (2027-2032) & (K Units) Table 57. Global Attenuated Vaccine Sales Market Share in Volume by Application (2027-2032) Table 58. Global Attenuated Vaccine Sales by Application (2027-2032) & (US$ Million) Table 59. Global Attenuated Vaccine Sales Market Share in Value by Application (2027-2032) Table 60. Global Attenuated Vaccine Price by Application (2027-2032) & (US$/Unit) Table 61. North America Attenuated Vaccine Sales by Application (2021-2026) & (K Units) Table 62. North America Attenuated Vaccine Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Attenuated Vaccine Sales by Application (2021-2026) & (K Units) Table 64. Europe Attenuated Vaccine Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Attenuated Vaccine Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Attenuated Vaccine Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Attenuated Vaccine Sales by Application (2021-2026) & (K Units) Table 68. Latin America Attenuated Vaccine Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Attenuated Vaccine Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Attenuated Vaccine Sales by Application (2021-2026) & (US$ Million) Table 71. Changchun BCHT Biotechnology Co.,Ltd Company Information Table 72. Changchun BCHT Biotechnology Co.,Ltd Business Overview Table 73. Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Product Portfolio Table 75. Changchun BCHT Biotechnology Co.,Ltd Recent Development Table 76. Shanghai Rongsheng Biotech Company Information Table 77. Shanghai Rongsheng Biotech Business Overview Table 78. Shanghai Rongsheng Biotech Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Shanghai Rongsheng Biotech Attenuated Vaccine Product Portfolio Table 80. Shanghai Rongsheng Biotech Recent Development Table 81. Sanofi Company Information Table 82. Sanofi Business Overview Table 83. Sanofi Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Sanofi Attenuated Vaccine Product Portfolio Table 85. Sanofi Recent Development Table 86. Johnson & Johnson Company Information Table 87. Johnson & Johnson Business Overview Table 88. Johnson & Johnson Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Johnson & Johnson Attenuated Vaccine Product Portfolio Table 90. Johnson & Johnson Recent Development Table 91. Merck & Co. Company Information Table 92. Merck & Co. Business Overview Table 93. Merck & Co. Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Merck & Co. Attenuated Vaccine Product Portfolio Table 95. Merck & Co. Recent Development Table 96. Pfizer Inc Company Information Table 97. Pfizer Inc Business Overview Table 98. Pfizer Inc Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Pfizer Inc Attenuated Vaccine Product Portfolio Table 100. Pfizer Inc Recent Development Table 101. GlaxoSmithKline plc Company Information Table 102. GlaxoSmithKline plc Business Overview Table 103. GlaxoSmithKline plc Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. GlaxoSmithKline plc Attenuated Vaccine Product Portfolio Table 105. GlaxoSmithKline plc Recent Development Table 106. Serum Institute of India Pvt. Ltd. Company Information Table 107. Serum Institute of India Pvt. Ltd. Business Overview Table 108. Serum Institute of India Pvt. Ltd. Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Serum Institute of India Pvt. Ltd. Attenuated Vaccine Product Portfolio Table 110. Serum Institute of India Pvt. Ltd. Recent Development Table 111. Green Cross Corporation Company Information Table 112. Green Cross Corporation Business Overview Table 113. Green Cross Corporation Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Green Cross Corporation Attenuated Vaccine Product Portfolio Table 115. Green Cross Corporation Recent Development Table 116. CSL Limited Company Information Table 117. CSL Limited Business Overview Table 118. CSL Limited Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. CSL Limited Attenuated Vaccine Product Portfolio Table 120. CSL Limited Recent Development Table 121. Biken Company Information Table 122. Biken Business Overview Table 123. Biken Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Biken Attenuated Vaccine Product Portfolio Table 125. Biken Recent Development Table 126. Astellas Pharma Company Information Table 127. Astellas Pharma Business Overview Table 128. Astellas Pharma Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Astellas Pharma Attenuated Vaccine Product Portfolio Table 130. Astellas Pharma Recent Development Table 131. North America Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 132. North America Attenuated Vaccine Sales by Country (2021-2026) & (K Units) Table 133. North America Attenuated Vaccine Sales Market Share by Country (2021-2026) Table 134. North America Attenuated Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 135. North America Attenuated Vaccine Sales Market Share Forecast by Country (2027-2032) Table 136. North America Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. North America Attenuated Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 138. North America Attenuated Vaccine Market Share by Country (2021-2026) Table 139. North America Attenuated Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. North America Attenuated Vaccine Market Share Forecast by Country (2027-2032) Table 141. Europe Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 142. Europe Attenuated Vaccine Sales by Country (2021-2026) & (K Units) Table 143. Europe Attenuated Vaccine Sales Market Share by Country (2021-2026) Table 144. Europe Attenuated Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 145. Europe Attenuated Vaccine Sales Market Share Forecast by Country (2027-2032) Table 146. Europe Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Europe Attenuated Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 148. Europe Attenuated Vaccine Market Share by Country (2021-2026) Table 149. Europe Attenuated Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Europe Attenuated Vaccine Market Share Forecast by Country (2027-2032) Table 151. Asia-Pacific Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 152. Asia-Pacific Attenuated Vaccine Sales by Country (2021-2026) & (K Units) Table 153. Asia-Pacific Attenuated Vaccine Sales Market Share by Country (2021-2026) Table 154. Asia-Pacific Attenuated Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 155. Asia-Pacific Attenuated Vaccine Sales Market Share Forecast by Country (2027-2032) Table 156. Asia-Pacific Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Asia-Pacific Attenuated Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 158. Asia-Pacific Attenuated Vaccine Market Share by Country (2021-2026) Table 159. Asia-Pacific Attenuated Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Asia-Pacific Attenuated Vaccine Market Share Forecast by Country (2027-2032) Table 161. Latin America Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 162. Latin America Attenuated Vaccine Sales by Country (2021-2026) & (K Units) Table 163. Latin America Attenuated Vaccine Sales Market Share by Country (2021-2026) Table 164. Latin America Attenuated Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 165. Latin America Attenuated Vaccine Sales Market Share Forecast by Country (2027-2032) Table 166. Latin America Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Latin America Attenuated Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 168. Latin America Attenuated Vaccine Market Share by Country (2021-2026) Table 169. Latin America Attenuated Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Latin America Attenuated Vaccine Market Share Forecast by Country (2027-2032) Table 171. Middle East and Africa Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 172. Middle East and Africa Attenuated Vaccine Sales by Country (2021-2026) & (K Units) Table 173. Middle East and Africa Attenuated Vaccine Sales Market Share by Country (2021-2026) Table 174. Middle East and Africa Attenuated Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 175. Middle East and Africa Attenuated Vaccine Sales Market Share Forecast by Country (2027-2032) Table 176. Middle East and Africa Attenuated Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Middle East and Africa Attenuated Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 178. Middle East and Africa Attenuated Vaccine Market Share by Country (2021-2026) Table 179. Middle East and Africa Attenuated Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Middle East and Africa Attenuated Vaccine Market Share Forecast by Country (2027-2032) Table 181. Key Raw Materials Table 182. Raw Materials Key Suppliers Table 183. Attenuated Vaccine Distributors List Table 184. Attenuated Vaccine Customers List Table 185. Research Programs/Design for This Report Table 186. Authors List of This Report Table 187. Secondary Sources Table 188. Primary Sources List of Figures Figure 1. Attenuated Vaccine Image Figure 2. Global Attenuated Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Attenuated Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Attenuated Vaccine Sales (2021-2032) & (K Units) Figure 5. Bacterial Vaccine Image Figure 6. Global Bacterial Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 7. Viral Vaccine Image Figure 8. Global Viral Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Attenuated Vaccine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Attenuated Vaccine Market Share by Type 2025 VS 2032 Figure 11. North America Attenuated Vaccine Sales Market Share in Volume by Type in 2025 Figure 12. North America Attenuated Vaccine Sales Market Share in Value by Type in 2025 Figure 13. Europe Attenuated Vaccine Sales Market Share in Volume by Type in 2025 Figure 14. Europe Attenuated Vaccine Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Attenuated Vaccine Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Attenuated Vaccine Sales Market Share in Value by Type in 2025 Figure 17. Latin America Attenuated Vaccine Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Attenuated Vaccine Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Attenuated Vaccine Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Attenuated Vaccine Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Attenuated Vaccine Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Image Figure 24. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 25. Clinic Image Figure 26. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 27. Others Image Figure 28. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Attenuated Vaccine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Attenuated Vaccine Market Share by Application 2025 VS 2032 Figure 31. North America Attenuated Vaccine Sales Market Share in Volume by Application in 2025 Figure 32. North America Attenuated Vaccine Sales Market Share in Value by Application in 2025 Figure 33. Europe Attenuated Vaccine Sales Market Share in Volume by Application in 2025 Figure 34. Europe Attenuated Vaccine Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Attenuated Vaccine Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Attenuated Vaccine Sales Market Share in Value by Application in 2025 Figure 37. Latin America Attenuated Vaccine Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Attenuated Vaccine Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Attenuated Vaccine Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Attenuated Vaccine Sales Market Share in Value by Application in 2025 Figure 41. North America Attenuated Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Attenuated Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Attenuated Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Attenuated Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Attenuated Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Attenuated Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Attenuated Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Attenuated Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Attenuated Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Attenuated Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Attenuated Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Attenuated Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Attenuated Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Attenuated Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Attenuated Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Attenuated Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Attenuated Vaccine Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Attenuated Vaccine Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Bacterial Vaccine
  • Viral Vaccine
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Changchun BCHT Biotechnology Co.,Ltd
  • Shanghai Rongsheng Biotech
  • Sanofi
  • Johnson & Johnson
  • Merck & Co.
  • Pfizer Inc
  • GlaxoSmithKline plc
  • Serum Institute of India Pvt. Ltd.
  • Green Cross Corporation
  • CSL Limited
  • Biken
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Attenuated Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Attenuated Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Attenuated Vaccine Market by Type
  6. 1.3.1 Bacterial Vaccine
  7. 1.3.2 Viral Vaccine
  8. 1.4 Global Attenuated Vaccine Market Size by Type
  9. 1.4.1 Global Attenuated Vaccine Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Attenuated Vaccine Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Attenuated Vaccine Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Attenuated Vaccine Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Attenuated Vaccine Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Attenuated Vaccine Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Attenuated Vaccine Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Attenuated Vaccine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Attenuated Vaccine Industry Trends
  2. 2.2 Attenuated Vaccine Industry Drivers
  3. 2.3 Attenuated Vaccine Industry Opportunities and Challenges
  4. 2.4 Attenuated Vaccine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Attenuated Vaccine Revenue (2021-2026)
  2. 3.2 Global Top Players by Attenuated Vaccine Sales (2021-2026)
  3. 3.3 Global Top Players by Attenuated Vaccine Price (2021-2026)
  4. 3.4 Global Attenuated Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Attenuated Vaccine Major Company Production Sites & Headquarters
  6. 3.6 Global Attenuated Vaccine Company, Product Type & Application
  7. 3.7 Global Attenuated Vaccine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Attenuated Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Attenuated Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Attenuated Vaccine Tier 1, Tier 2, and Tier 3
4 Attenuated Vaccine Regional Status and Outlook
  1. 4.1 Global Attenuated Vaccine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Attenuated Vaccine Historic Market Size by Region
  3. 4.2.1 Global Attenuated Vaccine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Attenuated Vaccine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Attenuated Vaccine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Attenuated Vaccine Forecasted Market Size by Region
  7. 4.3.1 Global Attenuated Vaccine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Attenuated Vaccine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Attenuated Vaccine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Attenuated Vaccine by Application
  1. 5.1 Attenuated Vaccine Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Attenuated Vaccine Market Size by Application
  6. 5.2.1 Global Attenuated Vaccine Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Attenuated Vaccine Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Attenuated Vaccine Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Attenuated Vaccine Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Attenuated Vaccine Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Attenuated Vaccine Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Attenuated Vaccine Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Attenuated Vaccine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Changchun BCHT Biotechnology Co.,Ltd
  2. 6.1.1 Changchun BCHT Biotechnology Co.,Ltd Company Information
  3. 6.1.2 Changchun BCHT Biotechnology Co.,Ltd Business Overview
  4. 6.1.3 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Product Portfolio
  6. 6.1.5 Changchun BCHT Biotechnology Co.,Ltd Recent Developments
  7. 6.2 Shanghai Rongsheng Biotech
  8. 6.2.1 Shanghai Rongsheng Biotech Company Information
  9. 6.2.2 Shanghai Rongsheng Biotech Business Overview
  10. 6.2.3 Shanghai Rongsheng Biotech Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Shanghai Rongsheng Biotech Attenuated Vaccine Product Portfolio
  12. 6.2.5 Shanghai Rongsheng Biotech Recent Developments
  13. 6.3 Sanofi
  14. 6.3.1 Sanofi Company Information
  15. 6.3.2 Sanofi Business Overview
  16. 6.3.3 Sanofi Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Sanofi Attenuated Vaccine Product Portfolio
  18. 6.3.5 Sanofi Recent Developments
  19. 6.4 Johnson & Johnson
  20. 6.4.1 Johnson & Johnson Company Information
  21. 6.4.2 Johnson & Johnson Business Overview
  22. 6.4.3 Johnson & Johnson Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Johnson & Johnson Attenuated Vaccine Product Portfolio
  24. 6.4.5 Johnson & Johnson Recent Developments
  25. 6.5 Merck & Co.
  26. 6.5.1 Merck & Co. Company Information
  27. 6.5.2 Merck & Co. Business Overview
  28. 6.5.3 Merck & Co. Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Merck & Co. Attenuated Vaccine Product Portfolio
  30. 6.5.5 Merck & Co. Recent Developments
  31. 6.6 Pfizer Inc
  32. 6.6.1 Pfizer Inc Company Information
  33. 6.6.2 Pfizer Inc Business Overview
  34. 6.6.3 Pfizer Inc Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Inc Attenuated Vaccine Product Portfolio
  36. 6.6.5 Pfizer Inc Recent Developments
  37. 6.7 GlaxoSmithKline plc
  38. 6.7.1 GlaxoSmithKline plc Company Information
  39. 6.7.2 GlaxoSmithKline plc Business Overview
  40. 6.7.3 GlaxoSmithKline plc Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 GlaxoSmithKline plc Attenuated Vaccine Product Portfolio
  42. 6.7.5 GlaxoSmithKline plc Recent Developments
  43. 6.8 Serum Institute of India Pvt. Ltd.
  44. 6.8.1 Serum Institute of India Pvt. Ltd. Company Information
  45. 6.8.2 Serum Institute of India Pvt. Ltd. Business Overview
  46. 6.8.3 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Product Portfolio
  48. 6.8.5 Serum Institute of India Pvt. Ltd. Recent Developments
  49. 6.9 Green Cross Corporation
  50. 6.9.1 Green Cross Corporation Company Information
  51. 6.9.2 Green Cross Corporation Business Overview
  52. 6.9.3 Green Cross Corporation Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Green Cross Corporation Attenuated Vaccine Product Portfolio
  54. 6.9.5 Green Cross Corporation Recent Developments
  55. 6.10 CSL Limited
  56. 6.10.1 CSL Limited Company Information
  57. 6.10.2 CSL Limited Business Overview
  58. 6.10.3 CSL Limited Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 CSL Limited Attenuated Vaccine Product Portfolio
  60. 6.10.5 CSL Limited Recent Developments
  61. 6.11 Biken
  62. 6.11.1 Biken Company Information
  63. 6.11.2 Biken Business Overview
  64. 6.11.3 Biken Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Biken Attenuated Vaccine Product Portfolio
  66. 6.11.5 Biken Recent Developments
  67. 6.12 Astellas Pharma
  68. 6.12.1 Astellas Pharma Company Information
  69. 6.12.2 Astellas Pharma Business Overview
  70. 6.12.3 Astellas Pharma Attenuated Vaccine Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Astellas Pharma Attenuated Vaccine Product Portfolio
  72. 6.12.5 Astellas Pharma Recent Developments
7 North America by Country
  1. 7.1 North America Attenuated Vaccine Sales by Country
  2. 7.1.1 North America Attenuated Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Attenuated Vaccine Sales by Country (2021-2026)
  4. 7.1.3 North America Attenuated Vaccine Sales Forecast by Country (2027-2032)
  5. 7.2 North America Attenuated Vaccine Market Size by Country
  6. 7.2.1 North America Attenuated Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Attenuated Vaccine Market Size by Country (2021-2026)
  8. 7.2.3 North America Attenuated Vaccine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Attenuated Vaccine Sales by Country
  2. 8.1.1 Europe Attenuated Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Attenuated Vaccine Sales by Country (2021-2026)
  4. 8.1.3 Europe Attenuated Vaccine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Attenuated Vaccine Market Size by Country
  6. 8.2.1 Europe Attenuated Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Attenuated Vaccine Market Size by Country (2021-2026)
  8. 8.2.3 Europe Attenuated Vaccine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Attenuated Vaccine Sales by Country
  2. 9.1.1 Asia-Pacific Attenuated Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Attenuated Vaccine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Attenuated Vaccine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Attenuated Vaccine Market Size by Country
  6. 9.2.1 Asia-Pacific Attenuated Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Attenuated Vaccine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Attenuated Vaccine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Attenuated Vaccine Sales by Country
  2. 10.1.1 South America Attenuated Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Attenuated Vaccine Sales by Country (2021-2026)
  4. 10.1.3 South America Attenuated Vaccine Sales Forecast by Country (2027-2032)
  5. 10.2 South America Attenuated Vaccine Market Size by Country
  6. 10.2.1 South America Attenuated Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Attenuated Vaccine Market Size by Country (2021-2026)
  8. 10.2.3 South America Attenuated Vaccine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Attenuated Vaccine Sales by Country
  2. 11.1.1 Middle East and Africa Attenuated Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Attenuated Vaccine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Attenuated Vaccine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Attenuated Vaccine Market Size by Country
  6. 11.2.1 Middle East and Africa Attenuated Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Attenuated Vaccine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Attenuated Vaccine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Attenuated Vaccine Value Chain Analysis
  2. 12.1.1 Attenuated Vaccine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Attenuated Vaccine Production Mode & Process
  7. 12.2 Attenuated Vaccine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Attenuated Vaccine Distributors
  10. 12.2.3 Attenuated Vaccine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst